

References

- Abbas, A. K., et al. (2015). *Cellular and molecular immunology*. Elsevier.
- Aisyah, D. N., et al. (2020). A spatial-temporal description of the SARS-COV-2 infections in Indonesia during the first six months of outbreak. *PLOS ONE*, 15(12). <https://doi.org/10.1371/journal.pone.0243703>
- Altschul, S. F., et al. (1990). Basic local alignment search tool. *Journal of Molecular Biology*, 215(3), 403–410. [https://doi.org/10.1016/s0022-2836\(05\)80360-2](https://doi.org/10.1016/s0022-2836(05)80360-2)
- Arts, R. J. W., et al. (2018). BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. *Cell Host & Microbe*, 23(1). <https://doi.org/10.1016/j.chom.2017.12.010>
- Birra, D., et al. (2020). Covid 19: A clue from innate immunity. *Immunologic Research*, 68(3), 161–168. <https://doi.org/10.1007/s12026-020-09137-5>
- Boechat, J. L., Chora, I., Morais, A., & Delgado, L. (2021). The immune response to SARS-COV-2 and COVID-19 immunopathology – current perspectives. *Pulmonology*, 27(5), 423–437. <https://doi.org/10.1016/j.pulmoe.2021.03.008>
- Brant, A. C., et al. (2021). SARS-COV-2: From its discovery to genome structure, transcription, and replication. *Cell & Bioscience*, 11(1). <https://doi.org/10.1186/s13578-021-00643-z>
- Comunale, B. A., et al. (2021). Poliovirus vaccination induces a humoral immune response that cross reacts with SARS-COV-2. *Frontiers in Medicine*, 8. <https://doi.org/10.3389/fmed.2021.710010>
- Fisker, A. (2022). *OPV as potential protection against COVID-19 - Full Text View*. Full Text View - ClinicalTrials.gov. Retrieved May 23, 2022, from <https://clinicaltrials.gov/ct2/show/NCT04445428>

- Ganesh, B., et al. (2021). Epidemiology and pathobiology of SARS-COV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. *Clinical Epidemiology and Global Health*, 10, 100694. <https://doi.org/10.1016/j.cegh.2020.100694>
- Gonzalez-Galarza, et al. (2019). Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and New Query Tools. *Nucleic Acids Research*. <https://doi.org/10.1093/nar/gkz1029>
- Grifoni, A., et al. (2020). Targets of T cell responses to SARS-COV-2 coronavirus in humans with covid-19 disease and unexposed individuals. *Cell*, 181(7). <https://doi.org/10.1016/j.cell.2020.05.015>
- Haddad-Boubaker, S., et al. (2021). In silico comparative study of SARS-COV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: Evidence of a possible putative protective effect. *BMC Bioinformatics*, 22(1). <https://doi.org/10.1186/s12859-021-04045-3>
- Harrison, A. G., Lin, T., & Wang, P. (2020). Mechanisms of SARS-COV-2 transmission and pathogenesis. *Trends in Immunology*, 41(12), 1100–1115. <https://doi.org/10.1016/j.it.2020.10.004>
- Hikmawati, I., & Setiyabudi, R. (2021). Epidemiology of covid-19 in Indonesia: Common source and propagated source as a cause for outbreaks. *The Journal of Infection in Developing Countries*, 15(05), 646–652. <https://doi.org/10.3855/jidc.14240>
- Holland, C. J., Cole, D. K., & Godkin, A. (2013). Re-directing CD4+ T cell responses with the flanking residues of MHC class II-bound peptides: The core is not enough. *Frontiers in Immunology*, 4. <https://doi.org/10.3389/fimmu.2013.00172>
- Kissler, S. M., et al. (2020). Projecting the transmission dynamics of SARS-COV-2 through the post

- pandemic period. *Science*, 368(6493), 860–868. <https://doi.org/10.1126/science.abb5793>
- Lipsitch, M., Grad, Y. H., Sette, A., & Crotty, S. (2020). Cross-reactive memory T cells and herd immunity to SARS-COV-2. *Nature Reviews Immunology*, 20(11), 709–713. <https://doi.org/10.1038/s41577-020-00460-4>
- Lundberg, L., et al. (2021). Recent MMR vaccination in health care workers and covid-19: A test negative case-control study. *Vaccine*, 39(32), 4414–4418. <https://doi.org/10.1016/j.vaccine.2021.06.045>
- Mak, T. W., & Saunders, M. E. (2006). Vaccines and clinical immunization. *The Immune Response*, 695–749. <https://doi.org/10.1016/b978-012088451-3.50025-9>
- Malave Sanchez, M., Saleeb, P., Kottilil, S., & Mathur, P. (2021). Oral polio vaccine to protect against COVID-19: Out of the box strategies? *Open Forum Infectious Diseases*, 8(8). <https://doi.org/10.1093/ofid/ofab367>
- Milinski, M., et al. (2005). Mate choice decisions of stickleback females predictably modified by MHC peptide ligands. *Proceedings of the National Academy of Sciences*, 102(12), 4414–4418. <https://doi.org/10.1073/pnas.0408264102>
- Murphy, K., & Weaver, C. (2017). *Janeway's Immunobiology*. Garland Science, Taylor & Francis Group.
- Murray, M. (2021). *BCG against covid-19 for prevention and amelioration of severity trial (BAC to the past) - full text view*. Full Text View - ClinicalTrials.gov. Retrieved May 23, 2022, from <https://clinicaltrials.gov/ct2/show/NCT04534803>
- Naqvi, A. A., et al. (2020). Insights into SARS-COV-2 genome, structure, evolution, pathogenesis and therapies: Structural Genomics Approach. *Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1866(10), 165878. <https://doi.org/10.1016/j.bbadis.2020.165878>

- NCBI Resource Coordinators (2016). Database resources of the National Center for Biotechnology Information. *Nucleic acids research*, 44(D1), D7–D19. <https://doi.org/10.1093/nar/gkv1290>
- Reynisson, B., et al. (2020). Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. *Journal of Proteome Research*, 19(6), 2304–2315. <https://doi.org/10.1021/acs.jproteome.9b00874>
- Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*, 109, 102433. <https://doi.org/10.1016/j.jaut.2020.102433>
- Ryu, W.-S. (2017). New emerging viruses. *Molecular Virology of Human Pathogenic Viruses*, 289–302. <https://doi.org/10.1016/b978-0-12-800838-6.00021-7>
- Sette, A., & Crotty, S. (2021). Adaptive immunity to SARS-COV-2 and COVID-19. *Cell*, 184(4), 861–880. <https://doi.org/10.1016/j.cell.2021.01.007>
- Shah, V. K., et al. (2020). Overview of immune response during SARS-COV-2 infection: Lessons from the past. *Frontiers in Immunology*, 11. <https://doi.org/10.3389/fimmu.2020.01949>
- Sidiq, K. R., Sabir, D. K., Ali, S. M., & Kodzius, R. (2020). Does early childhood vaccination protect against covid-19? *Frontiers in Molecular Biosciences*, 7. <https://doi.org/10.3389/fmolb.2020.00120>
- Stranzl, T., et al. (2010). NetCTLpan: Pan-specific MHC class I pathway epitope predictions. *Immunogenetics*, 62(6), 357–368. <https://doi.org/10.1007/s00251-010-0441-4>
- Tomita, Y., Sato, R., Ikeda, T., & Sakagami, T. (2020). BCG vaccine may Generate cross-reactive T cells AGAINST Sars-cov-2: In silico analyses and a hypothesis. *Vaccine*, 38(41), 6352–6356. <https://doi.org/10.1016/j.vaccine.2020.08.045>